A Decade of Reinforcing Business Integrity Making Asia-Pacific better prepared for COVID-19
Over the last decade the Asia-Pacific has seen an unprecedented shift in the adoption and implementation of high-standard ethical business conduct across its healthcare enterprises, including in the biopharmaceutical sector. This positive uptake of integrity had positioned the region to better prepare for, and now to hope to recover from, the current pandemic.
Related news and resources
How we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
The socio-economic value of adult immunisation programmes
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read more